title: Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD.
abstract: OBJECTIVE
  To evaluate the effect of intraperitoneal (IP) administration of heparin on clearance of advanced glycation end-products (AGEs) and peritoneal dialysis efficiency.
  
  
  METHODS
  Sequential self-controlled intervention study.
  
  
  METHODS
  University hospital, Department of Nephrology.
  
  
  METHODS
  Pyrraline, urea, and creatinine levels in plasma and dialysate, along with AGE-derived fluorescence intensity (excitation, 370 nm; emission, 440 nm) in dialysate were measured 0, 30, and 60 days after IP administration of heparin in 11 patients on continuous ambulatory peritoneal dialysis (CAPD). Pyrraline levels were determined by ELISA.
  
  
  RESULTS
  Heparin induced a significant decrease in plasma pyrraline levels; the values on days 0, 30, and 60 were 162.0+/-89.8 micromol/L, 101.1+/-32.1 micromol/L (p < 0.01), and 94.0+/-19.8 micromol/L (p < 0.001), respectively. Heparin also induced a tendency of increased dialysate pyrraline levels and a significant increase in AGE-derived fluorescence intensity in the dialysate. The values for the latter on days 0, 30, and 60 were 51.0+/-9.3 AU (arbitrary units/ mg of collagen), 73.5+/-16.0 AU (p < 0.001), and 65.6+/-15.5 AU (p < 0.01), respectively. Furthermore, heparin administration resulted in a significant (p < 0.01) increase in the dialysate/plasma ratio of urea (means 0.80, 0.90, and 0.94 on days 0, 30, and 60, respectively).
  
  
  CONCLUSIONS
  These results suggest that a beneficial effect of IP administration of heparin is in part due to its action on AGE kinetics, supporting a potential preventive strategy for peritoneal membrane distortion in CAPD.
authors.affiliation: Department of Nephrology, Toho University School of Medicine, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mizuiri
authors.forename: S
authors.initials: S
authors.lastname: Miyata
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Miyagi
authors.forename: T
authors.initials: T
authors.lastname: Nakanishi
authors.forename: B F
authors.initials: BF
authors.lastname: Liu
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: A
authors.initials: A
authors.lastname: Hasegawa
mesh_terms: D003404:Creatinine / Q000032:analysis / Q000097:blood; D015314:Dialysis Solutions / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000032:analysis* / Q000097:blood; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D009646:Norleucine / Q000031:analogs & derivatives / Q000032:analysis / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011758:Pyrroles / Q000032:analysis / Q000097:blood; D014508:Urea / Q000032:analysis / Q000097:blood
chemical_list: D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D011758:Pyrroles; C059571:2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine; D009646:Norleucine; D014508:Urea; D006493:Heparin; D003404:Creatinine